Author argues LEXX could 2-8x via a licensing deal or buyout tied to its GLP-1 side-effect treatment and an MTA with a likely PharmaCo (possibly Novo) giving first purchase option until April 30.
LEXX — LONG Author claims LEXX's recently released results show a significant decrease in side effects for people on GLP-1 fat drugs using their treatment, positioning them in the race to move GLP-1 to oral intake. LEXX entered a Material Transfer Agreement giving an unnamed 'PharmaCo' (likely Novo) exclusive access to positive results data and a first option to purchase LEXX until April 30, which the author sees as a potential licensing agreement or buyout catalyst within 3 months. Author estimates buyout targets of 2x-8x today's $0.75 price, with investor meetings starting next week as a possible announcement window. Main stated risk is that biotech is fickle and readers should do their own research.
This MTA gives "PharmaCo" exclusive access to their recent positive results data, and first option to purchase LEXX until April 30.
This Reddit post, published January 21, 2026, features u/newtownkid discussing LEXX. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/newtownkid · Tickers: LEXX